In his keynote lecture from this year’s International Research Congress on FSHD, held virtually on June 25-26, George Padberg, MD, regarded as the father of modern FSHD research, shared observations from his four decades of seeing patients and directing ground-breaking research. Now retired from UMC St. Radboud in the Netherlands, Dr. Padberg was invited to… Read More »
A giant of FSHD research shares his “regrets”
UCLA Health – Southern California’s Frontlines of FSHD Research
Nestled into a basement in an outpatient building at UCLA Health’s Westwood hospitals is UCLA Neurology, home to ground-breaking FSHD Research. UCLA Health already ranks as the #1 hospital in California, and 4th nationally according to the U.S. News & World Report’s 2020 rankings, but it is also part of an elite network of… Read More »
Fulcrum’s interim findings from ReDUX4 trial are “encouraging”
This week, Fulcrum Therapeutics announced results from an interim analysis of data collected from its Phase 2 ReDUX4 trial, which is testing the effect of a drug called losmapimod in individuals with facioscapulohumeral muscular dystrophy (FSHD). The drug, which is taken as a pill twice a day, is intended to reduce the expression of a… Read More »
FSHD Clinical Trial Research Network expands to four new sites
The FSHD Society announced today that it has awarded $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on funding of $300,000 a year in 2021 and 2022. The network is a consortium of academic research centers in the United States and Europe with expertise in FSHD clinical… Read More »
ReDUX4 clinical trial update
In this video, Diego Cadavid, MD, Senior Vice President, Clinical Development, at Fulcrum Therapeutics provides an update on ReDUX4, the Phase 2b clinical trial currently underway testing the safety and efficacy of losmapimod to treat facioscapulohumeral muscular dystrophy (FSHD). The company started recruiting volunteers for the trial in August of 2019 and completed enrollment in… Read More »